FDA Seeks To Enhance Reporting Of Pediatric Adverse Events

In addition to the Adverse Event Reporting System, FDA may collect pediatric safety data from other surveillance databases and Phase IV trials. Options to improve safety reporting will be a topic for future discussion by the Pediatric Advisory Committee.